1 / 15

NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems. NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences

lonato
Download Presentation

NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE?Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences Senior Research Scientist, Stanford / VA Aging Clinical Research Stanford University and VA Palo Alto Health Care System January 5, 2010 Slides at: www.medafile.com(Dr. Ashford’s lectures)

  2. Alzheimer pathology affects regions of the cortex that have a high capacity and responsibility for memory storage Sensory, Perception, Memory systems of cortex – Ashford, Coburn, Fuster, 1998

  3. BIOPSYCHOSOCIAL SYSTEMS AFFECTED BY ADNEUROPLASTIC MECHANISMS AFFECTED AT ALL LEVELS (Ashford, Mattson, Kumar, 1998) • SOCIAL SYSTEMS • INSTRUMENTAL ADLs - EARLY • BASIC ADLs - LATE • PSYCHOLOGICAL SYSTEMS • PRIMARY LOSS OF SHORT-TERM MEMORY • LEARNING PROCESSES – CLASSICAL, OPERANT • LATER LOSS OF LEARNED SKILLS • NEURONAL MEMORY SYSTEMS • CORTICAL GLUTAMATERGIC STORAGE • SUBCORTICAL • (acetylcholine, norepinephrine, serotonin) • CELLULAR PLASTIC PROCESSES • APP metabolism – early, broad cortical distribution • TAU hyperphosphorylation – late, focal effect, dementia related

  4. intracellular extra cellular APP – formed during learning - XS in Downs Lipid raft Formed by cholesterol Transported by ApoE (from macroglia) Alpha-secretase is stimulated by acetylcholine through muscarinic receptor Residual (not processed by a-secretase) NEXIN ? To establish new connections Amyloid –beta: ? Free-radical generator ? To remove old synapses Turn-over – 8 hours Clearance – IDE, APOE Favored when lipid raft too thick JW Ashford, MD PhD, 2007

  5. Acetylcholine activity stimulates alpha-secretase and inhibits tau phosphorylation

  6. ALZHEIMER’S DISEASE COURSE AAMI / MCI/ early AD -- DEMENTIA Ashford et al., 1995

  7. PATHOLOGY IN DENDRITES RELATES TO HIGH VOLUMES OF TRANSPORT TO SUPPORT SYNAPTIC PLASTICITY Shown on the next slides is a view which reflects observations from a double labeling (with PHF-1 and MAP-2) analysis of neurons in the cortex affected by Alzheimer’s disease (Ashford et al., 1998).

  8. Ashford et al., 1998 J Neuropathol Exp Neurol.57:972

  9. Progression of tau hyperphosphorylation to neuropil threads and neurofibrillary tangles Ashford et al., 1998, J Neuropathol Exp Neurol.57:972

  10. APOE, Alzheimer Hypothesis • APOE (apo-lipo-protein E) is a cholesterol chaperone • Cholesterol metabolsim is a central part of synaptic plasticity (Koudinov & Koudinov, 2001) • APOE genotype has a strongly established relationship with AD risk • CAVEAT – the APOE protein variations (e2, e3, e4) do not have a clear role in the causation of Alzheimer pathology

  11. JW Ashford, MD PhD, 2003; See: Raber et al., 2004

  12. JW Ashford, MD PhD, 2003

  13. e4/4 – 2% of pop, 20% of cases e3/4 - 20% of pop, 40% of cases e3/3 - 65% of pop, 35% of cases JW Ashford, MD PhD, 2000

  14. APOE AND EVOLUTION(The original allele was APOE-e4, the e3 allele appeared about 300,000 years ago, and the e2 allele appeared about 200,000 years ago) • Does APOE-e2 or e3 do a safer job of supporting the remodelling of dendrites, to minimize the stress on a neuron over time? • Demented elderly cannot foster their young or compete • APOE AS AN AGENT TO SUPPORT SUCCESSFUL AGING IN GRANDMOTHERS • APOE AS AN AGENT TO SUPPORT THE DOMINANCE OF ELDERLY MALES OVER YOUNGER MALES • APOE genotype may be in close linkage-dysequilibrium with a neighboring gene that is specifically responsible for the vulnerability to Alzheimer’s disease (possibly TOMM-40)

More Related